



**Date: February 28, 2025**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 40 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 (“the Listing Regulations”)**

---

In continuation to our earlier communication dated May 12, 2023, we would like to inform you that the Company has received an order from Income Tax department for Assessment Year 2021-22.

The detailed disclosure required as per Regulation 30 of the Listing Regulations read with Master Circular No. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated November 11, 2024 as amended from time to time is enclosed herewith as **Annexure-I**.

This is for your kind information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**

**Company Secretary and Compliance Officer**

**Encl.: A/a**

**ANNEXURE-I**

<b>Sr. No.</b>	<b>Details of event that needs to be provided</b>	<b>Details</b>
1	Name of the authority	Office of the Dy. Commissioner of Income Tax, Central Circle 29, New Delhi (“IT Authority”)
2	Nature and details of the action(s) taken, initiated or order(s) passed;	AY 2021-22
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Order dated February 25, 2025 (Received on February 27, 2025 through IT Portal)
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The IT Authority vide assessment order dated February 25, 2025 has raised additional tax demand (including interest) of INR 111.68 crores under section 143(3) read with Section 144C(3) of the Income-tax Act, 1961 (‘the Act’) on account of adjustment made u/s 80IC/80IE of the Act and disallowance of various expenditures u/s 37(1) of the Act.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	The Company believe that the demand under the above referred Order is not tenable in law. The Company has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or operations of the Company due to the said order. The Company would pursue appeal against the said order under the applicable laws.

**MANKIND PHARMA LIMITED**